Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease

Histopathology

Volumn 44, Issue 4, 2004, Pages 345-352

  Lumb, P D ^a   Suvarna, S K ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Catenin; CD147; Ki67; Matrix metalloproteinase; Mesothelioma; Metastasis; nm23

Indexed keywords

ALPHA CATENIN; CADHERIN; CD147 ANTIGEN; GELATINASE B; MONOCLONAL ANTIBODY KI 67; POLYCLONAL ANTIBODY; PROTEIN BCL 2;

ARTICLE; BIOPSY; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PATHOLOGIST; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD147; ANTIGENS, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MESOTHELIOMA; NEOPLASM METASTASIS; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 1842844367     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01844.x     Document Type: Article

References (55)

1. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality In Britain. Lancet 1995: 345; 535-539.
2. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in South East England: clinicopathological experience of 272 cases. Thorax 1997: 52; 507-512.
3. Hasleton PS. Pleural disease. In Hasleton PS ed. Spencer's pathology of the lung, 5th edn. New York: McGraw-Hill. 1996; 1154-1210.
4. Sussman J, Rosai J. Lymph node metastasis as the initial manifestation of malignant mesothelioma: report of six cases. Am. J. Surg. Pathol. 1990: 14; 819-828.
5. Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen. MIB-1, and E-cadherin immunohistochemical determination. Clin. Cancer Res. 1996: 2; 1801-1808.
6. Jensen V, Sorensen FB, Bentzen S et al. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 1998: 32; 536-546.
7. Boni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J. Am. Acad. Dermatol. 1996: 35; 416-418.
8. Puglisi F, Aprile G, Bruckbauer M et al. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett. 2001: 162; 97-103.
9. Kayser G, Gunzenhauser I, Becker HD, Herth F, Kayser K. Proliferation rate of small cell lung carcinoma. A cytomorphometric parameter with prognostic significance. Pathologe 2001: 22; 326-332.
10. Schiller AB, Clark WS, Cotsonis G et al. Image cytometric bcl-2 : bax and bcl-2 : bcl-x ratios in invasive breast carcinoma: correlation with prognosis. Cytometry 2002: 50; 203-209.
11. Manne U, Weiss HL, Grizzle WE. bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int. J. Cancer 2000: 89; 423-430.
12. Vlaykova T, Talve L, Hahka-Kemppinen M et al. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology 2002: 62; 259-268.
13. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J. Thor. Cardiovasc. Surg. 2002: 123; 1191-1198.
14. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Resp. Cell Mol. Biol. 2001: 25; 562-568.
15. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am. J. Physiol. 1998: 275; 165-171.
16. Huang G, Mo W, Kuang G et al. Expression of p16, nm23-H1, E-cadherin and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 2001: 111; 1465-1471.
17. Kauffman E, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW, Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 2003: 169; 1122-1133.
18. Leone A, Flatow U, King CR et al. Reduced tumour incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991: 65; 25-39.
19. Graham ANJ, Maxwell P, Mulholland K et al. Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination. J. Clin. Pathol. 2002: 55; 184-190.
20. Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe P. Protein markers in colorectal cancer: predictors of liver metastasis. Ann. Surg. 1999: 230; 179-184.
21. Tas F, Tuzlali S, Aydiner A et al. Prognostic role of nm23 gene expression in patients with ovarian cancer. Am. J. Clin. Oncol. 2002: 25; 164-167.
22. Ayhan A, Yasui W, Yokozaki H, Kitadai Y, Tahara E. Reduced expression of nm23 protein is associated with advanced tumour stage and distant metastases in human colorectal carcinomas. Virchows Arch. B Cell Pathol. 1993: 63; 213-218.
23. Ikeguchi M, Makino M, Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J. Surg. Oncol 2001: 77; 201-207.
24. Zhang XD, Hersey P. Expression of catenins and p120cas in melanocytic nevi and cutaneous melanoma: deficient alpha-catenin expression is associated with melanoma progression. Pathology 1999: 31; 239-246.
25. Pignatelli M, Integrins, cadherins and catenins: molecular cross talk in cancer cells. J. Pathol. 1998: 186; 1-2.
26. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997: 57; 3189-3193.
27. El-Bahrawy M, Talbot I, Poulsom R, Alison M. Variable nuclear localization of alpha-catenin in colorectal carcinoma. Lab. Invest. 2002: 82; 1167-1174.
28. Hirano H, Tsuji M, Kizaki T et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med. Electron Microscopy 2002: 35; 16-23.
29. Bagutti C, Speight PM, Watt FM. Comparison of integrin, cadherin and catenin expression in squamous cell carcinoma of the oral cavity, J. Pathol. 1998: 185; 618-661.
30. Lui Z, Ivanoff A, Klominek J. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int. J. Cancer 2001: 91; 638-642.
31. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001: 61; 2276-81.
32. Caudroy S, Polette M, Tournier JM et al. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J. Histochem. Cytochem. 1999: 47; 1575-80.
33. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer 1982: 49; 2431-2435,
34. Kumar-Singh S, Jacobs W, Dhaene K et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation. WT1 expression, and clinical outcome. J. Pathol. 1998: 186; 300-305.
35. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001: 38; 535-541.
36. Kaarteenaho-Wiik R, Soini Y, Pöllänen R, Pääkkö P, Kinnula VL. Over-expression of tenascin-C in malignant pleural mesothelioma. Histopathology 2003: 42; 280-291.
37. Beer TW, Buchanan R, Matthews AW et al. Prognosis in malignant mesothelioma related to MIB-1 proliferation index and histological subtype. Hum. Pathol. 1998: 29; 246-251.
38. Kumar-Singh S, Vermeulen PB, Weyler J et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J. Pathol. 1997: 182; 211-216.
39. Comin CE, Anichini C, Boddi V, Novelli L, Dini S. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000: 36; 26-31.
40. Kahlos K, Soini Y, Paakko P et al. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int. J. Cancer 2000: 88; 37-43.
41. Soini Y, Kinnula V, Kaarteenaho-Wiik R et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X and bax in malignant mesothelioma. Clin. Cancer Res. 1999: 5; 3508-3515.
42. Segers K, Ramael M, Singh SK et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch. 1994: 424; 631-634.
43. Chilosi M, Facchettti F, Dei Tos AP et al. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J. Pathol. 1997: 181; 362-367.
44. Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in-situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 1999: 189; 251-257.
45. Fouret P, Temam S, Charlotte F, Lacau-St-Guily J. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br. J. Cancer 2002: 87; 1390-1395.
46. Urakami S, Igawa M, Shirakawa H, Shiina H, Kawanishi M. Quantitative analysis of nm23 protein immunoreactivity in renal cell carcinoma using an image analyzer. J. Urol. 1997: 157; 1928-1931.
47. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br. J. Cancer 2000: 83; 1147-1153.
48. Thorns C, Feller AC, Merz H. EMMPRIN (CD147) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma. An immunohistochemical study of 60 cases. Anticancer Res. 2002: 22; 1983-1986.
49. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumour cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 2002: 99; 520-528.
50. Böhm J, Niskanen L, Kiraly K et al. Expression and prognostic value of [alpha]-, [beta]-, and [gamma]-catenins in differentiated thyroid carcinoma. J. Clin. Endocrin. Metab. 2000: 85; 4806-4811.
51. Kahlos K, Soini Y, Sormunen R et al. Expression and prognostic significance of catalase in malignant mesothelioma. Cancer 2001: 91; 1349-1357.
52. Sington JD, Morris LS, Nicholson AG, Coleman N. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003: 42; 498-502.
53. Roberts F, McCall AE, Burnett RA. Malignant mesothelioma; a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J. Clin. Pathol. 2001: 54; 776-780.
54. Gordon GJ, Jensen RV, Hsiao LL et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl Cancer Inst. 2003: 95; 598-605.
55. Gordon GJ, Jensen RV, Hsiao LL et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002: 62; 4963-4967.